Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Receivables (2016 - 2025)

Historic Receivables for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $11.6 billion.

  • Bristol Myers Squibb's Receivables fell 701.81% to $11.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.6 billion, marking a year-over-year decrease of 701.81%. This contributed to the annual value of $11.6 billion for FY2025, which is 701.81% down from last year.
  • Bristol Myers Squibb's Receivables amounted to $11.6 billion in Q4 2025, which was down 701.81% from $13.2 billion recorded in Q3 2025.
  • Bristol Myers Squibb's Receivables' 5-year high stood at $13.2 billion during Q3 2025, with a 5-year trough of $9.5 billion in Q2 2022.
  • In the last 5 years, Bristol Myers Squibb's Receivables had a median value of $11.2 billion in 2022 and averaged $11.3 billion.
  • Per our database at Business Quant, Bristol Myers Squibb's Receivables crashed by 821.63% in 2022 and then soared by 2456.02% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Receivables stood at $10.8 billion in 2021, then increased by 8.01% to $11.6 billion in 2022, then fell by 2.44% to $11.3 billion in 2023, then rose by 10.1% to $12.5 billion in 2024, then fell by 7.02% to $11.6 billion in 2025.
  • Its last three reported values are $11.6 billion in Q4 2025, $13.2 billion for Q3 2025, and $13.1 billion during Q2 2025.